T. Kadia

Susan O'Brien, Gautam Borthakur, Marina Konopleva, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, Cancer.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Leukemia & lymphoma.

A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2007 .

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Jorge Cortes, Guillermo Garcia-Manero, Gautam Borthakur, 2013, Blood.

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of Hematology & Oncology.

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Journal of Hematology & Oncology.

Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Clinical lymphoma, myeloma & leukemia.

Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Cancer.

Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Acta Haematologica.

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management

H. Kantarjian, T. Kadia, E. Jabbour, 2019, Cancer.

Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, American journal of hematology.

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma

M. Konopleva, T. Kadia, E. Jabbour, 2017, Case reports in hematology.

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014, Leukemia research.

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation

P. Sharma, Z. Estrov, J. Blando, 2018, Blood.

Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma

T. Kadia, V. Gandhi, 2017, Expert review of hematology.

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).

Xiuqiang Wang, H. Kantarjian, J. Cortes, 2010 .

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials

T. Kadia, N. Pemmaraju, C. Rausch, 2020, Expert opinion on emerging drugs.

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

M. Konopleva, K. Patel, T. Kadia, 2020, Frontiers in Oncology.

Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Clinical Observations of AML Expressing Mutant RUNX1 and Pre-Clinical Studies of RUNX1-Targeted Novel Therapy of AML.

K. Bhalla, H. Kantarjian, K. Patel, 2017 .

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

H. Kantarjian, T. Kadia, F. Ravandi, 2018, Leukemia.

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias

M. Konopleva, H. Kantarjian, J. Cortes, 2020, Acta Haematologica.

Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study.

M. Konopleva, H. Kantarjian, Xuelin Huang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

A. Verma, H. Kantarjian, J. Cortes, 2009 .

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

J. Cortes, T. Kadia, M. Keating, 2016, Oncotarget.

Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.

M. Konopleva, M. Andreeff, H. Kantarjian, 2014 .

Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review

T. Kadia, P. Boddu, 2017, Expert review of hematology.

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Y. Qi, B. Ebert, Xiaoping Su, 2022, Blood cancer journal.

Development of TP53 mutations over the course of therapy for acute myeloid leukemia

M. Konopleva, T. Kadia, F. Ravandi, 2021, American journal of hematology.

Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

M. Konopleva, M. Andreeff, K. Bhalla, 2019, Journal of Clinical Oncology.

Recent Developments in Drug Therapy for Aplastic Anemia

T. Kadia, Amber Rexwinkle, Jeffrey C. Bryan, 2014, The Annals of pharmacotherapy.

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

M. Konopleva, H. Kantarjian, K. Patel, 2020, American journal of hematology.

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

M. Konopleva, M. Andreeff, K. Bhalla, 2020, Blood cancer discovery.

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

R. Collins, M. Konopleva, Z. Estrov, 2016 .

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Z. Estrov, H. Kantarjian, J. Cortes, 2014 .

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.

G. Garcia-Manero, Xuelin Huang, K. Patel, 2022, The Lancet. Haematology.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

G. Fuller, M. Konopleva, H. Kantarjian, 2017, American journal of hematology.

Alemtuzumab in T-cell large granular lymphocyte leukaemia.

T. Kadia, F. Ravandi, 2016, The Lancet. Haematology.

A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Release the hounds: virotherapy with immunotherapy.

T. Kadia, 2016, Blood.

complementing the known mutational inactivation of S1PR2 in GC-DLBCL with a newmechanism ofS1PR2 silencing involving transcriptional suppression by FOXP1 in ABC-DLBCL and providing direct evidence of its role as tumor suppressor in this

Brown, Green, T. Kadia, 2016 .

Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL).

C. Wilson, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014 .

Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia

K. Bhalla, K. Patel, T. Kadia, 2022, American journal of hematology/oncology.

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Leukemia & lymphoma.

A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy

T. Kadia, F. Ravandi, C. Dinardo, 2022, American journal of hematology.

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, Leukemia & lymphoma.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

J. Welch, M. Konopleva, M. Andreeff, 2020, Haematologica.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, S. Colla, H. Kantarjian, 2018, Blood.

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group.

M. Andreeff, H. Kantarjian, J. Cortes, 2017, Blood advances.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

K. Rezvani, G. Garcia-Manero, Xuelin Huang, 2022, The Lancet. Haematology.

Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Response kinetics and factors predicting survival in core-binding factor leukemia

H. Kantarjian, G. Garcia-Manero, K. Patel, 2018, Leukemia.

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case–control study

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2013, American journal of hematology.

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Andrew T Nguyen, B. Ebert, Jianhua Zhang, 2022, Blood.

Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, T. Kadia, F. Ravandi, 2020 .

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

M. Konopleva, H. Kantarjian, J. Cortes, 2020 .

Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology/oncology.

Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.

M. Konopleva, M. Andreeff, H. Kantarjian, 2013 .

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.

Naveen Garg, M. Konopleva, Z. Estrov, 2021, JAMA oncology.

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL

D. Marin, T. Kadia, E. Jabbour, 2017, Bone Marrow Transplantation.

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

O. Lichtarge, K. Do, M. Andreeff, 2020, Blood Cancer Journal.

Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens

T. Kadia, F. Ravandi, G. Borthakur, 2022, American journal of hematology.

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies

H. Kantarjian, T. Kadia, E. Jabbour, 2022, Cancer.

T. Kadia, F. Ravandi, E. Jabbour, 2020, Leukemia & lymphoma.

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, Cancer.

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Cancer.

Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2015, Cancer.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2019, Blood.

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Blood.

Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation

T. Kadia, F. Ravandi, E. Jabbour, 2018, Journal of Clinical Pathology.

Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, American journal of hematology.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Oncotarget.

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

M. Minden, G. Curt, H. Kantarjian, 2012, Investigational New Drugs.

Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission

H. Kantarjian, E. Shpall, K. Patel, 2022, American journal of hematology.

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

M. Konopleva, H. Kantarjian, G. Martinelli, 2021, Frontiers in Oncology.

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

M. Konopleva, T. Kadia, F. Ravandi, 2020, Cancer discovery.

Treating Leukemia in the Time of COVID-19

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Acta Haematologica.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2019, Blood advances.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, The Lancet. Haematology.

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach

H. Kantarjian, T. Kadia, F. Ravandi, 2021, Cancer.

Acute myeloid leukemia: current progress and future directions

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood Cancer Journal.

Maintenance Therapy in AML

T. Kadia, P. Reville, 2021, Frontiers in Oncology.

Progress in acute myeloid leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2015, Clinical lymphoma, myeloma & leukemia.

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts

M. Minden, H. Kantarjian, T. Kadia, 2015, American journal of hematology.

Frontline treatment of acute myeloid leukemia in adults.

M. Konopleva, H. Kantarjian, J. Cortes, 2017, Critical reviews in oncology/hematology.

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survival

M. Konopleva, H. Kantarjian, M. Routbort, 2018, American journal of hematology.

Which FLT3 Inhibitor for Treatment of AML?

T. Kadia, Jayastu Senapati, J. Senapati, 2022, Current Treatment Options in Oncology.

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022 .

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

S. Devlin, S. Verstovsek, T. Kadia, 2018, Blood.

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

P. Venugopal, M. Buyse, G. Gaidano, 2021, Cancer.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

G. Garcia-Manero, T. Kadia, N. Daver, 2021, Leukemia.

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

P. Qiu, K. Rajapakshe, C. Coarfa, 2016, Leukemia.

Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

H. Kantarjian, R. Luthra, K. Patel, 2012, Cancer.

Outcomes of patients with chronic lymphocytic leukemia treated with first‐line idelalisib plus rituximab after cessation of treatment for toxicity

F. Stingo, T. Kadia, M. Keating, 2016, Cancer.

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin

M. Konopleva, M. Andreeff, H. Kantarjian, 2012, Cancer.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

A. Letai, M. Konopleva, H. Kantarjian, 2016, Cancer discovery.

Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, American journal of hematology.

Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Cancer.

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2021, British journal of haematology.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Cancer.

RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Michael R. Green, K. Rajapakshe, C. Coarfa, 2019, Blood.

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Blood.

Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy

Fern, H. Kantarjian, T. Kadia, 2017 .

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2020, Modern Pathology.

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

J. Welch, M. Konopleva, Z. Estrov, 2020, The Lancet. Haematology.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

M. Konopleva, S. Colla, H. Kantarjian, 2019, Blood advances.

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Z. Estrov, Jianhua Zhang, Xingzhi Song, 2019, Blood Cancer Journal.

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

M. Konopleva, J. Cortes, T. Kadia, 2021, Journal of Hematology & Oncology.

Central nervous system Richter’s transformation and parvovirus B19 infection

Lin Pei, Z. Estrov, T. Kadia, 2013, Leukemia & lymphoma.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Xuelin Huang, Guillermo Garcia-Manero, Gautam Borthakur, 2016, British journal of haematology.

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Y. Qi, B. Ebert, Xiaoping Su, 2022, Blood Cancer Journal.

MYC protein expression is an important prognostic factor in acute myeloid leukemia

Z. Estrov, M. Andreeff, K. Bhalla, 2019, Leukemia & lymphoma.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Blood.

Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

M. Konopleva, Z. Estrov, D. Marin, 2017, JAMA oncology.

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2009 .

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2015, American journal of hematology.

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, American journal of hematology.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, International Journal of Hematology.

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

Significance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Leukemia & lymphoma.

Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, K. Patel, 2023, Cancer.

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

H. Kantarjian, T. Kadia, F. Ravandi, 2021, Cancer.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

P. Qiu, M. Konopleva, M. Andreeff, 2016, American journal of hematology.

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Cancer.

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

P. Vyas, C. Craddock, R. Majeti, 2022, Cancer discovery.

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2014, Clinical lymphoma, myeloma & leukemia.

Phase 1 and Extension Study of Clofarabine plus Cyclophosphamide in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia ( ALL )

J. Cortes, T. Kadia, F. Ravandi, 2014 .

Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2.

Y. Qi, K. Bhalla, X. Su, 2021, Blood.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Blood advances.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, Cancer.

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS‐mutant Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Clinical lymphoma, myeloma & leukemia.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Naveen Garg, Rashmi Kanagal-Shamanna, Prithviraj Bose, 2019, The New England journal of medicine.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood Cancer Journal.

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Blood.

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

K. Pradhan, S. Demo, A. Verma, 2023, Research square.

The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy

G. Garcia-Manero, T. Kadia, F. Tambaro, 2010, Clinical Cancer Research.

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

M. Konopleva, Z. Estrov, Jianhua Zhang, 2016, Oncotarget.

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood advances.

Immunotherapy in Acute Myeloid Leukemia: Where We Stand

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).

U. Jaeger, M. Mayerhoefer, T. Kadia, 2019, Blood.

Future prospects of therapeutic clinical trials in acute myeloid leukemia.

T. Kadia, Maliha Khan, A. Mansoor, 2017, Future oncology.

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Blood.

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, International journal of molecular sciences.

More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate.

E. Estey, T. Kadia, H. Klepin, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, Cancer.

Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial

M. Konopleva, G. Garcia-Manero, T. Kadia, 2015 .

Role of epigenetic therapy in myelodysplastic syndrome

G. Garcia-Manero, T. Kadia, 2008, Expert review of hematology.

Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors

T. Kadia, E. Jabbour, L. Medeiros, 2022, Leukemia & lymphoma.

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

Z. Estrov, T. Kadia, G. Borthakur, 2018, Leukemia.

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53

Z. Estrov, H. Kantarjian, K. Patel, 2019, Blood.

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, M. Andreeff, H. Kantarjian, 2017 .

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

Naveen Garg, M. Konopleva, Z. Estrov, 2021, Leukemia.

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Z. Estrov, H. Kantarjian, K. Patel, 2018, Blood.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

G. Garcia-Manero, T. Kadia, M. Keating, 2009 .

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, BioMed research international.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

E. Estey, G. Lenz, H. Dombret, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies.

P. Vyas, H. Kantarjian, T. Kadia, 2022, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood cancer journal.

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Blood.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2021, Blood cancer discovery.

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

M. Konopleva, M. Andreeff, K. Bhalla, 2022, Blood advances.

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2020 .

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection

T. Kadia, N. Daver, H. Abbas, 2019, Cancer management and research.

CMAR_A_177894 8817..8828

T. Kadia, N. Daver, H. Abbas, 2019 .

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.

M. Konopleva, H. Kantarjian, J. Cortes, 2020, Blood advances.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Blood.

Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL)

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, T. Kadia, 2022, Journal of Clinical Oncology.

Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, American journal of hematology.

Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab

M. Konopleva, H. Kantarjian, T. Kadia, 2022, American journal of hematology.

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.

C. Mullighan, M. Konopleva, H. Kantarjian, 2020, The Lancet. Haematology.

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2019, Blood.

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Haematologica.

Identifying effective drug combinations for patients with acute myeloid leukemia

T. Kadia, F. Ravandi, M. Yilmaz, 2020, Expert review of anticancer therapy.

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Erika J. Thompson, M. Konopleva, K. Bhalla, 2020, Nature Communications.

Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

M. Konopleva, K. Rezvani, D. Marin, 2021, Blood.

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2021, Haematologica.

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)

G. Garcia-Manero, T. Kadia, F. Ravandi, 2021, Blood.

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Blood.

A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Cancer.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

P. Sharma, M. Konopleva, Z. Estrov, 2019, The Lancet. Haematology.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Cancer.

Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

T. Kadia, P. Jain, F. Ravandi, 2020, Leukemia & lymphoma.

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia

T. Kadia, D. Grosshans, B. Dabaja, 2012, BMJ Case Reports.

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

P. Venugopal, H. Kantarjian, T. Kadia, 2012 .

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2011 .

Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.

G. Garcia-Manero, J. Cortes, T. Kadia, 2011, Journal of Clinical Oncology.

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

M. Konopleva, T. Kadia, F. Ravandi, 2022, Blood advances.

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, American journal of hematology.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Leukemia.

Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults

M. Konopleva, H. Kantarjian, J. Cortes, 2015 .

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021, Blood Advances.

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

P. A. Futreal, S. Ogawa, Jianhua Zhang, 2018, Blood.

Aplastic anemia following the severe acute respiratory syndrome coronavirus‐2 vaccine

T. Kadia, K. Sasaki, P. Thompson, 2022, EJHaem.

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.

M. Konopleva, Z. Estrov, M. Andreeff, 2016, Clinical lymphoma, myeloma & leukemia.

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

M. Konopleva, G. Garcia-Manero, E. Shpall, 2022, Journal of Hematology & Oncology.

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, The Lancet. Haematology.

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia.

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Haematologica.

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Z. Estrov, S. Colla, H. Kantarjian, 2017, American journal of hematology.

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

M. Konopleva, M. Andreeff, K. Bhalla, 2020 .

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2021, Cancer.

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2020, bioRxiv.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

K. Do, M. Konopleva, H. Kantarjian, 2020, American journal of hematology.

Early detection of transformation to BPDCN in a patient with MDS

M. Konopleva, M. Andreeff, T. Kadia, 2018, Experimental Hematology & Oncology.

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Cancer.

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.

H. Kantarjian, J. Cortes, T. Kadia, 2015, JAMA oncology.

Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, American journal of hematology.

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

D. Wheeler, P. Qiu, M. Konopleva, 2014, Leukemia and Lymphoma.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Hoang Q. Nguyen, P. Thall, E. Estey, 2015, Haematologica.

Clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph-) emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017 .

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

R. Chen, Z. Estrov, H. Kantarjian, 2013, American journal of hematology.

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Journal of Hematology & Oncology.

Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia

T. Kadia, J. Burger, N. Pemmaraju, 2019, Leukemia & lymphoma.

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2022, Blood.

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Z. Estrov, G. Garcia-Manero, J. Cortes, 2009 .

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2009 .

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020

Marina, M. Andreeff, H. Kantarjian, 2020, Indian Journal of Hematology and Blood Transfusion.

The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy

G. Garcia-Manero, T. Kadia, Hui Yang, 2010, Autophagy.

A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Cancer.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2019, American journal of hematology.

The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors

G. Garcia-Manero, K. Patel, T. Kadia, 2023, American journal of hematology.

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Blood.

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Blood.

A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018 .

Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase

M. Konopleva, H. Kantarjian, J. Cortes, 2017 .

Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

M. Konopleva, H. Kantarjian, J. Cortes, 2007 .

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020 .

Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

S. Devlin, S. Verstovsek, T. Kadia, 2019, Blood.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Z. Estrov, K. Bhalla, H. Kantarjian, 2018, Blood.

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Blood.

Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B‐cell acute lymphoblastic leukemia

C. Mullighan, T. Kadia, F. Ravandi, 2023, American journal of hematology.

Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

Guillermo Garcia-Manero, Angela Teng, H. Kantarjian, 2015, Leukemia & lymphoma.

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Association between bariatric surgery and outcomes in chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Cancer.

Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement.

T. Kadia, Sa A. Wang, R. Miranda, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2019, Blood.

Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

T. Kadia, P. Reville, 2020, Current Treatment Options in Oncology.

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Leukemia research.

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012 .

Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib.

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).

Z. Estrov, H. Kantarjian, J. Cortes, 2016 .

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, bioRxiv.

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.

Jacob G. Scott, T. Haferlach, H. Kantarjian, 2021, Blood.

Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2009 .

Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2011 .

Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial

C. Mullighan, M. Konopleva, H. Kantarjian, 2017 .

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Naveen Garg, Catherine J. Wu, P. Sharma, 2022, Blood advances.

Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, American journal of hematology.

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).

P. A. Futreal, M. Konopleva, H. Kantarjian, 2019, Blood.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2023, The Lancet. Haematology.

Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group.

A. Bagg, W. Tam, D. Arber, 2023, JCO precision oncology.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2013 .

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Blood.

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Dapsone induced methemoglobinemia in a patient with glioblastoma

T. Kadia, Julie G. Walker, J. Groot, 2009, Journal of Neuro-Oncology.

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood.

Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study

M. Konopleva, H. Kantarjian, J. Cortes, 2018, Blood.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, American journal of hematology.

Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, American journal of hematology.

Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

M. Konopleva, H. Kantarjian, J. Cortes, 2018 .

Differential Coupling of Serotonin 5‐HT1A and 5‐HT1B Receptors to Activation of ERK2 and Inhibition of Adenylyl Cyclase in Transfected CHO Cells

D. S. Cowen, T. Kadia, Jorge Mendez, 1999, Journal of neurochemistry.

Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology/oncology.

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis

P. Hari, S. Parmar, S. Verstovsek, 2019, Blood.

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, British journal of haematology.

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood Cancer Journal.

Multiple recurrent extra‐medullary relapses of high‐grade diffuse large B‐cell lymphoma presenting in acute leukemic phase

H. Kantarjian, T. Kadia, P. Jain, 2013, American journal of hematology.

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Xiaoping Su, K. Bhalla, T. Kadia, 2023, Leukemia.

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Blood.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response

P. Sharma, M. Konopleva, M. Andreeff, 2020 .

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Xiaoping Su, K. Bhalla, T. Kadia, 2023, Blood cancer journal.

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Cancer.

Validation of a clinical assay of multi‐locus DNA methylation for prognosis of newly diagnosed AML

G. Wertheim, M. Carroll, M. Konopleva, 2017, American journal of hematology.

Early Treatment with Ofatumumab in Patients with High-Risk CLL

M. Konopleva, Z. Estrov, T. Kadia, 2022, Blood.

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

G. Garcia-Manero, J. Cortes, T. Kadia, 2022, American journal of hematology.

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

M. Konopleva, K. Bhalla, H. Kantarjian, 2023, Haematologica.

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements.

C. Mullighan, K. Patel, T. Kadia, 2023, JCO precision oncology.

AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34).

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Clinical lymphoma, myeloma & leukemia.

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

M. Konopleva, H. Kantarjian, T. Kadia, 2020 .

Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, Blood.

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD

Naveen Garg, T. Kadia, M. Keating, 2023, Leukemia.

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Blood advances.

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

J. Welch, M. Konopleva, M. Andreeff, 2019, Blood.

Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, American journal of hematology.

Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2017 .

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology/oncology.

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016 .

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Leukemia research.

Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2 nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

P. Sharma, M. Konopleva, Z. Estrov, 2017 .

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Cancers.

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood.

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2021, Blood.

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

M. Konopleva, H. Kantarjian, E. Shpall, 2023, Blood advances.

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.

G. Garcia-Manero, E. Shpall, T. Kadia, 2023, American journal of hematology.

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, Blood.

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, Leukemia.

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2020 .

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2019, Blood.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

T. Kadia, F. Ravandi, D. DeAngelo, 2015, Blood Cancer Journal.

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

M. Konopleva, K. Bhalla, H. Kantarjian, 2018, Blood.

First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies

T. Kadia, Jianxiang Wang, A. Zang, 2022, Blood.

Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies.

T. Kadia, F. Ravandi, C. Dinardo, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia

H. Kantarjian, T. Kadia, M. Keating, 2011 .

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higher-risk myelodysplastic syndrome (MDS).

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, Journal of Clinical Oncology.

Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.

A. Verma, H. Kantarjian, J. Cortes, 2011, Journal of Clinical Oncology.

Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, British journal of haematology.

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2018, Blood.

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).

Naveen Garg, M. Konopleva, Z. Estrov, 2019, Blood.

S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

M. Konopleva, Z. Estrov, T. Kadia, 2022, HemaSphere.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

P. Qiu, K. Rajapakshe, C. Coarfa, 2018, Leukemia.

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.

H. Kantarjian, J. Cortes, T. Kadia, 2015, JAMA oncology.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Leukemia & lymphoma.

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.

K. Patel, T. Kadia, E. Jabbour, 2023, American journal of hematology.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

H. Kantarjian, T. Kadia, E. Jabbour, 2011, Seminars in oncology.

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Oncotarget.

The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy

G. Garcia-Manero, T. Kadia, F. Tambaro, 2010, Clinical Cancer Research.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, The Lancet. Haematology.

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2016 .

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016, British journal of haematology.

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

M. Konopleva, Z. Estrov, H. Kantarjian, 2009 .

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

P. Qiu, M. Konopleva, M. Andreeff, 2016, American journal of hematology.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Journal of Clinical Oncology.

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY

M. Konopleva, Xuelin Huang, T. Kadia, 2023, HemaSphere.

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Journal of Clinical Oncology.

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2012 .

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias.

Z. Estrov, G. Garcia-Manero, T. Kadia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2020 .

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS

Jianhua Zhang, H. Kantarjian, G. Garcia-Manero, 2015 .

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Blood.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2023, Blood cancer discovery.

Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis.

T. Kadia, C. Dinardo, N. Jain, 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, American journal of hematology.

The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels

M. Konopleva, H. Kantarjian, T. Kadia, 2021 .

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Blood.

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Blood.

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2023, HemaSphere.